Home › Research › Down syndrome and Alzheimer's
[Effect of the chronic treatment with L-acetylcarnitine in Down's syndrome]
De Falco FA, D'Angelo E, Grimaldi G, Scafuro F, Sachez F, Caruso G.. La Clinica terapeutica, 1994-02-01
Topic: Brain proteins, microglia and lab models
Plain-language summary
Neuropsychologic tests were performed in subjects with Down syndrome in order to assess the effect of a 90-day treatment with L-acetyl-carnitine (LAC). Findings were evaluated statistically (Wilcoxon test) and compared to three further groups of subjects: untreated Down syndrome, mental deficiency due to other cases treated and not treated with LAC (Mann-Whitney U-test). Treated Down syndrome patients showed statistically significant improvements of visual memory and attention both in absolute terms and in comparison with the other groups. No improvement was found in mentally deficient non-Down subjects, so that the favourable effect of LAC appears to be specific for Down patients. In view of the analogies of the pathology and neurochemistry between Down syndrome and Alzheimer degenerative deficiency (deficit of cholinergic transmission) it is suggested that the action of LAC in these pathologies is related to its direct and indirect cholinomimetic effect.
What this study adds
Evidence grade: Low
This is a trial. In this small study, 90 days of treatment with L-acetyl-carnitine was associated with improved visual memory and attention in people with Down syndrome, but not in people with mental deficiency from other causes. The authors suggest a possible link to cholinergic transmission, but this does not demonstrate any treatment, cure or prevention for Alzheimer's disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
De Falco, F. A., D'Angelo, E., Grimaldi, G., Scafuro, F., Sachez, F., & Caruso, G. (1994). [Effect of the chronic treatment with L-acetylcarnitine in Down's syndrome]. La Clinica terapeutica.
Vancouver
De Falco FA, D'Angelo E, Grimaldi G, Scafuro F, Sachez F, Caruso G. [Effect of the chronic treatment with L-acetylcarnitine in Down's syndrome]. La Clinica terapeutica. 1994. PMID: 8181206.
BibTeX
@article{defalco1994-8181206,
author = {De Falco, F. A. and D'Angelo, E. and Grimaldi, G. and Scafuro, F. and Sachez, F. and Caruso, G.},
title = {{[Effect of the chronic treatment with L-acetylcarnitine in Down's syndrome]}},
journal = {La Clinica terapeutica},
year = {1994},
pmid = {8181206}
}
Built from the record alzhub holds for this paper, not looked up. This record has no DOI, so the citation leaves it out. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Findings were evaluated statistically (Wilcoxon test) and compared to three further groups of subjects: untreated Down syndrome, mental deficiency due to other cases treated and not treated with LAC (Mann-Whitney U-test).
- Treated Down syndrome patients showed statistically significant improvements of visual memory and attention both in absolute terms and in comparison with the other groups.
- In view of the analogies of the pathology and neurochemistry between Down syndrome and Alzheimer degenerative deficiency (deficit of cholinergic transmission) it is suggested that the action of LAC in these pathologies is related to its direct and indirect cholinomimetic effect.
Why it matters
In this small study, 90 days of treatment with L-acetyl-carnitine was associated with improved visual memory and attention in people with Down syndrome, but not in people with mental deficiency from other causes. The authors suggest a possible link to cholinergic transmission, but this does not demonstrate any treatment, cure or prevention for Alzheimer's disease.
Study details
- Evidence strengthLow
How this study scored 30/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported and randomized / blinded because the record does not state it. We have no data on journal's citation record and senior author's track record, so those were left out: it earned 28 of the 92 points we could judge it on, which is 30 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (La Clinica terapeutica) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 1994 — older than 20 years, still counted |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (pubmed indexes it as a clinical or observational study) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 3 / 7 | Cited 19 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.6 citations a year over 34 year(s) since 1994 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | 1 / 3 | University of Naples Federico II: institution h-index 862 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 8181206) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 28 / 92 | Scored on 18 of 20 parts. We have no data for the rest, so they are left out: 28 of the 92 points we could judge it on is 30 out of 100. |
| Total | 30 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Down syndrome and Alzheimer's from nearby years
Also tagged “down”
527 studies in the library carry the topic tag “down”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 527 tagged studies.